Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 18/20 | 0.70 |
| ▸ | CCNY | Q8ND76 | 16/20 | 0.70 |
| ▸ | CDK2 | P24941 | 3/20 | 0.70 |
| ▸ | CDK4 | P11802 | 2/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.70 |
| ▸ | CASK | O14936 | 1/20 | 0.70 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.70 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.70 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.70 |
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | MAK | P20794 | 1/20 | 0.70 |
| ▸ | CDK11B | P21127 | 1/20 | 0.70 |
| ▸ | CCND1 | P24385 | 1/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.70 |
| ▸ | CCND3 | P30281 | 1/20 | 0.70 |
| ▸ | CLK1 | P49759 | 1/20 | 0.70 |
| ▸ | CLK2 | P49760 | 1/20 | 0.70 |
| ▸ | CLK3 | P49761 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-7519 SCHEMBL29369459 | 0.86 | CDK14 (0.90) | CDK14CCNYCDK2CDK4CDK5 | |
| At-7519 SCHEMBL21134171 | 0.83 | CDK2 (1.00) | CDK14CCNYCDK2CDK4CDK5 | |
| At-7519 SCHEMBL29686205 | 0.82 | CDK2 (0.98) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL2029686 | 0.81 | CDK14 (0.48) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL4936632 | 0.79 | CDK14 (0.46) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL4199295 | 0.77 | CDK14 (0.47) | CDK14CCNYCDK2CDK4CDK5 | |
| At-7519 SCHEMBL30439334 | 0.77 | CDK2 (1.00) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL13993660 | 0.76 | LMNA (0.46) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL8262596 | 0.75 | CDK14 (0.43) | CDK14CCNYCDK2CDK4CDK5 | |
| SCHEMBL8261492 | 0.75 | CDK2 (0.49) | CDK14CCNYCDK2CDK4CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002918-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MIC60 DEPLETED CANCERS AND METASTASIS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2025-01-02 | — | — | US | claimed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| WO-2023070121-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MIC60 DEPLETED CANCERS AND METASTASIS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| EP-4582100-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119789868-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-08 | — | — | CN | disclosed |
| US-20250002918-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MIC60 DEPLETED CANCERS AND METASTASIS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2025-01-02 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| CN-116064902-A | dCAPS molecular marker for detecting upright plant type of Artemisia annua and application thereof | 河南大学 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023070121-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MIC60 DEPLETED CANCERS AND METASTASIS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20180066322-A1 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS | NOVARTIS AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150322528-A1 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | CDK14 1963/4885CCNY 1307/4885CDK2 1129/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | CDK14 160/4885CCNY 189/4885CDK2 170/4885 |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | CHI3L1, CHI3L2, ACE2 | CDK14 4651/4885CCNY 4782/4885CDK2 4490/4885 |
| US-20180066322-A1 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS | CDK3, CDK6, CDKL1 | CDK14 24/4885CCNY 50/4885CDK2 13/4885 |
| US-20150322528-A1 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS | CDK3, CDK6, CDKL1 | CDK14 24/4885CCNY 50/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.